cta5 Antibody

What is CTAGE5 and what is its biological significance?

CTAGE5 (Cutaneous T cell lymphoma-associated antigen 5) is a member of the cTAGE family that functions as a tumor-associated antigen overexpressed in various cancer cell lines. Structurally, CTAGE5 consists of a signal anchor motif, a single transmembrane domain, two coiled-coil motifs, and a proline-rich domain (PRD) from the N-terminus. Research has shown that CTAGE5 interacts with TANGO1 through its second coil region to form a cargo receptor complex, which plays a crucial role in cellular transport mechanisms . The calculated molecular weight of CTAGE5 is 92 kDa, though it is typically observed at 100-110 kDa in experimental conditions .

What are the validated applications for CTAGE5 antibody in research?

Based on comprehensive validation studies, CTAGE5 antibody (55279-1-AP) has been successfully employed in multiple experimental applications:

This versatility enables researchers to investigate CTAGE5 expression and function across multiple experimental platforms .

What are the optimal dilution ratios for different experimental applications?

For optimal experimental results when working with CTAGE5 antibody, researchers should consider the following recommended dilutions:

It's important to note that these ranges serve as starting points, and researchers should titrate the antibody for their specific experimental systems to achieve optimal results .

What antigen retrieval methods are recommended for IHC applications?

For immunohistochemistry applications using CTAGE5 antibody, specific antigen retrieval protocols have been validated:

• Primary recommendation: TE buffer at pH 9.0

• Alternative method: Citrate buffer at pH 6.0

These retrieval methods are essential for unmasking epitopes in formalin-fixed, paraffin-embedded (FFPE) tissues. The choice between these methods may depend on specific tissue types and fixation conditions .

How should researchers validate CTAGE5 antibody specificity in experimental designs?

Antibody validation is critical for ensuring reliable research outcomes. For CTAGE5 antibody, a multi-faceted validation approach is recommended:

• Expression correlation: Verify signal intensity correlates with known CTAGE5 expression patterns across different cell lines (HEK-293T, HepG2, PC-3)

• Molecular weight verification: Confirm that detected bands in Western blot correspond to the expected molecular weight (observed: 100-110 kDa; calculated: 92 kDa)

• Knockdown/knockout controls: Compare antibody signals between wild-type samples and those with reduced CTAGE5 expression (siRNA, CRISPR)

• Cross-application validation: Verify consistent detection across multiple applications (WB, IHC)

• Peptide competition assay: Verify that pre-incubation with the immunizing peptide abolishes specific signals

This comprehensive validation approach aligns with practices used for other well-characterized antibodies in research, such as those targeting complement components and viral receptors .

What are the critical parameters for optimizing Western blot protocols with CTAGE5 antibody?

For reliable and reproducible Western blot results with CTAGE5 antibody, researchers should consider these critical parameters:

• Sample preparation: Standard lysis buffers containing protease inhibitors are effective for CTAGE5 extraction. Loading 20-50 μg total protein per lane is recommended.

• Protein separation: 8-10% SDS-PAGE gels provide optimal resolution for the 100-110 kDa CTAGE5 protein.

• Transfer conditions: Semi-dry or wet transfer systems are suitable, with transfer times adjusted for the high molecular weight of CTAGE5.

• Blocking parameters:

  • Buffer: 5% non-fat milk or 3-5% BSA in TBST

  • Duration: 1 hour at room temperature

• Antibody incubation:

  • Primary antibody (CTAGE5): 1:1000-1:5000 dilution, overnight at 4°C

  • Secondary antibody: Anti-rabbit HRP conjugate at 1:5000, 1 hour at room temperature

• Detection considerations: CTAGE5 signal may require longer exposure times than typical housekeeping genes due to its expression level in most samples.

This methodological approach draws on established protocols for detecting high molecular weight proteins in complex samples, similar to approaches used with therapeutic antibodies and viral protein detection .

How can researchers quantitatively analyze CTAGE5 expression across different experimental conditions?

For rigorous quantitative analysis of CTAGE5 expression, researchers should implement:

• Standardized normalization strategy:

  • Housekeeping protein normalization (β-actin, GAPDH)

  • Total protein normalization methods for improved accuracy

  • Inclusion of technical replicates (minimum n=3)

• Image acquisition parameters:

  • Capture multiple exposure times to ensure signal is within linear range

  • Use high-resolution digital imaging systems with validated dynamic range

• Quantification workflow:

  • Employ dedicated analysis software (ImageJ, Image Studio)

  • Implement consistent background subtraction methods

  • Express results as fold-change relative to control conditions

• Statistical analysis:

  • Implement appropriate statistical tests based on experimental design

  • Report variability measures (standard deviation, standard error)

This quantitative approach aligns with methods used in antibody therapeutic research tracking, where precise quantification is essential for evaluating target engagement .

How does CTAGE5 expression pattern vary across normal and pathological conditions?

CTAGE5 expression exhibits distinct patterns across different tissues and disease states:

• Normal tissue distribution:

  • Detected in human brain tissue and testis tissue under normal conditions

  • Expression follows cell-type specific patterns within these tissues

• Pathological expression:

  • Significantly overexpressed in various cancer cell lines

  • Detected in human prostate cancer tissue through IHC analysis

  • Originally identified in association with cutaneous T cell lymphoma

• Subcellular localization:

  • Primarily localized to membrane structures due to transmembrane domain

  • Forms complexes with TANGO1 at specific cellular compartments

Understanding these expression patterns is critical for interpreting experimental results and evaluating CTAGE5 as a potential biomarker or therapeutic target .

What strategies should researchers employ when designing multiplex experiments incorporating CTAGE5 antibody?

When incorporating CTAGE5 antibody into multiplex experimental designs, researchers should consider:

• Antibody compatibility considerations:

  • Host species: CTAGE5 antibody (55279-1-AP) is a rabbit polyclonal antibody

  • Pair with antibodies from different host species for multiplex detection

  • If using multiple rabbit antibodies, implement sequential staining protocols

• Technical parameters for co-detection:

  • Optimize antibody concentrations individually before multiplexing

  • Validate absence of cross-reactivity with other primary antibodies

  • Test for potential epitope blocking in co-staining procedures

• Detection system selection:

  • For fluorescence: Choose fluorophores with minimal spectral overlap

  • For chromogenic detection: Use distinct substrates with good spatial separation

This approach follows principles established in advanced antibody research tracking methodologies where multiple targets are simultaneously monitored .

How can researchers integrate CTAGE5 antibody into therapeutic target validation studies?

For therapeutic target validation studies involving CTAGE5, researchers should implement:

• Expression-function relationship analysis:

  • Correlate CTAGE5 expression levels with cellular phenotypes

  • Investigate how CTAGE5-TANGO1 interactions influence disease mechanisms

  • Examine relationship between CTAGE5 expression and clinical parameters

• Target modulation approaches:

  • Use RNA interference to downregulate CTAGE5 expression

  • Employ CRISPR/Cas9 genome editing for complete knockout studies

  • Develop blocking antibodies targeting functional domains

• Validation in disease models:

  • Evaluate effects of CTAGE5 modulation in relevant disease models

  • Monitor downstream signaling pathways affected by CTAGE5 expression

  • Assess potential off-target effects of CTAGE5 targeting

This methodological framework draws from established approaches in antibody therapeutic development, where target validation is a critical step before clinical development .

What are the most common technical challenges when working with CTAGE5 antibody and how can they be addressed?

When working with CTAGE5 antibody, researchers frequently encounter these challenges:

• Non-specific binding in Western blot:

  • Increase blocking time/concentration (try 5% BSA instead of milk)

  • Optimize antibody dilution (start with 1:2000)

  • Include 0.1% Tween-20 in washing buffers

  • Use freshly prepared buffers

• Weak signal in IHC applications:

  • Compare TE buffer (pH 9.0) and citrate buffer (pH 6.0) for antigen retrieval

  • Extend primary antibody incubation time (overnight at 4°C)

  • Implement signal amplification systems

  • Optimize tissue fixation protocols for future samples

• Batch-to-batch variability:

  • Maintain detailed records of antibody lot numbers

  • Include internal reference samples across experiments

  • Consider pooling antibody aliquots for long-term studies

These troubleshooting approaches are consistent with quality control practices implemented in antibody-based therapeutic development .

What controls are essential when performing mechanistic studies with CTAGE5 antibody?

For rigorous mechanistic studies using CTAGE5 antibody, researchers should implement:

• Experimental controls:

  • Positive controls: Samples known to express CTAGE5 (HEK-293T, HepG2 cells)

  • Negative controls: No primary antibody, isotype control, CTAGE5-negative samples

  • Knockdown/knockout validation: siRNA or CRISPR-modified cells with reduced CTAGE5

• Technical validation controls:

  • Loading controls for protein quantification (β-actin, GAPDH)

  • Internal tissue controls for IHC applications

  • Peptide competition assays to confirm binding specificity

• Functional validation:

  • Correlation between protein detection and functional readouts

  • Multiple antibodies targeting different CTAGE5 epitopes

  • Complementary detection methods (RNA expression, protein activity)

This comprehensive control strategy aligns with approaches used in therapeutic antibody research and complement system studies .

How might CTAGE5 antibody be utilized in emerging single-cell analysis technologies?

CTAGE5 antibody has significant potential applications in single-cell analysis technologies:

• Single-cell proteomics applications:

  • Integration with CyTOF/mass cytometry panels for high-dimensional analysis

  • Application in imaging mass cytometry for spatial protein profiling

  • Incorporation into microfluidic antibody capture platforms

• Spatial biology approaches:

  • Multiplexed immunofluorescence with CTAGE5 and interacting partners

  • Digital spatial profiling to map CTAGE5 distribution in tissue microenvironments

  • Correlation with single-cell transcriptomics data

• Methodological considerations:

  • Antibody conjugation optimization for single-cell platforms

  • Validation of specificity at single-cell resolution

  • Development of computational analysis pipelines for CTAGE5 expression patterns

These emerging applications follow trends in advanced antibody research tracking methodologies, where single-cell resolution provides critical insights into heterogeneity of expression patterns .

What is the potential for developing CTAGE5-targeted therapeutic approaches based on antibody research?

Current research suggests several promising avenues for CTAGE5-targeted therapeutics:

• Antibody-drug conjugate (ADC) development:

  • CTAGE5's tumor-associated expression pattern makes it a candidate for ADC targeting

  • Research trends indicate growing interest in ADCs for solid tumors

  • Validation of internalization kinetics would be a critical step

• Functional blocking strategies:

  • Development of antibodies targeting the TANGO1-binding domain

  • Disruption of cargo transport functions in cancer cells

  • Combined targeting with other tumor-associated antigens

• Diagnostic applications:

  • Development of companion diagnostics for patient stratification

  • CTAGE5 expression as a potential biomarker for specific cancer subtypes

  • Integration with other molecular markers for improved specificity

This therapeutic development pathway would follow established frameworks used in antibody-based therapeutic development, as seen in other disease areas such as inflammatory arthritis and viral infections .